Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma

PTEN is a putative tumour suppressor gene located on chromosome band 10q23. Mutations in PTEN have been identified in numerous human malignancies, including cancers of the brain, endometrium, ovary, and prostate. In this study, we screened 80 Barrett’s oesophagus-associated adenocarcinomas (BOAd) for loss of heterozygosity (LOH) at 10q23, using the microsatellite markers D10S541, D10S219, and D10S551. Tumours demonstrating LOH were then screened for the presence or absence of PTEN mutations. LOH at one or more loci was identified in 17/80 (21%) cases. In none of these cases did we detect mutations in PTEN. The presence of LOH did not correlate with patient age, tumour stage, degree of differentiation, presence of perineural or vascular invasion, or overall survival. We conclude that LOH at chromosome 10q23 is uncommon in BOAd, is not associated with mutations in the PTEN tumour suppressor gene, and does not correlate with the clinical or pathologic features of these tumours. It is possible that PTEN is inactivated through other mechanisms in BOAd. © 2001 Cancer Research Campaign

[1]  C. Eng,et al.  Biallelic inactivating mutations and an occult germline mutation of PTEN in primary cervical carcinomas , 2000, Genes, chromosomes & cancer.

[2]  C. Eng,et al.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. , 2000, The American journal of pathology.

[3]  C. Eng,et al.  Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. , 2000, Journal of the National Cancer Institute.

[4]  J. Yeh,et al.  Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. , 2000, The American journal of pathology.

[5]  T. Takahashi,et al.  Abnormal structure and expression of PTEN/MMAC1 gene in human uterine cancers , 2000, Molecular carcinogenesis.

[6]  A. Okamoto,et al.  Allelic imbalance and mutations of the PTEN gene in ovarian cancer , 2000, International journal of cancer.

[7]  T. Dwight,et al.  Fine‐structure deletion mapping of 10q22–24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways , 1999 .

[8]  E. Zabarovsky,et al.  Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. , 1999, Anticancer research.

[9]  M. Loda,et al.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.

[10]  C Eng,et al.  PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. , 1999, Human molecular genetics.

[11]  M. Knowles,et al.  Somatic mutation of PTEN in bladder carcinoma , 1999, British Journal of Cancer.

[12]  M. Butler,et al.  Analysis of PTEN mutations and deletions in B‐cell non‐Hodgkin's lymphomas , 1999, Genes, chromosomes & cancer.

[13]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[14]  K. Joyce,et al.  Mutation in the PTEN/MMAC1 gene in archival low grade and high grade gliomas , 1999, British Journal of Cancer.

[15]  J. Ritz,et al.  PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. , 1999, Human molecular genetics.

[16]  A. Meindl,et al.  Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas , 1999, British Journal of Cancer.

[17]  H. Feilotter,et al.  Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma , 1999, British Journal of Cancer.

[18]  T. Dwight,et al.  Fine-structure deletion mapping of 10q22-24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways. , 1999, Genes, chromosomes & cancer.

[19]  K. Hoang-Xuan,et al.  Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. , 1999, International journal of cancer.

[20]  R. Maestro,et al.  Loss of heterozygosity at 10q in tumors of the upper respiratory tract is associated with poor prognosis. , 1999, International journal of cancer.

[21]  P. Goodfellow,et al.  PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. , 1998, Gynecologic oncology.

[22]  R. Eeles,et al.  Germline PTEN mutations in Cowden syndrome-like families. , 1998, Journal of medical genetics.

[23]  J. A. Hamilton,et al.  Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. , 1998, British Journal of Cancer.

[24]  H. Frierson,et al.  PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate , 1998, Oncogene.

[25]  R. Sutton,et al.  Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. , 1998, British Journal of Cancer.

[26]  R. Parsons,et al.  Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma , 1998, International journal of cancer.

[27]  T. Kinoshita,et al.  Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin’s lymphoma , 1998, Leukemia.

[28]  S. Petersen,et al.  Distinct regions of allelic imbalance on chromosome 10q22-q26 in squamous cell carcinomas of the lung , 1998, Oncogene.

[29]  David I. Smith,et al.  PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers , 1998, Oncogene.

[30]  H. Hibshoosh,et al.  Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas , 1998, Oncogene.

[31]  F. Haluska,et al.  Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines , 1998, Oncogene.

[32]  Erwin G. Van Meir,et al.  Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas , 1998, Oncogene.

[33]  J. Herman,et al.  Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers , 1998, Oncogene.

[34]  O. Cussenot,et al.  PTEN/MMAC1/TEP1 involvement in primary prostate cancers , 1998, Oncogene.

[35]  J. Yokota,et al.  Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers , 1998, Genes, chromosomes & cancer.

[36]  P. Guldberg,et al.  Alterations of the MMAC1/PTEN gene in lymphoid malignancies. , 1998, Blood.

[37]  G. Chenevix-Trench,et al.  Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. , 1998, Cancer research.

[38]  D. Louis,et al.  PTEN mutations in gliomas and glioneuronal tumors , 1998, Oncogene.

[39]  R. Vessella,et al.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Loda,et al.  Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. , 1998, Cancer research.

[41]  H. Feilotter,et al.  Analysis of PTEN and the 10q23 region in primary prostate carcinomas , 1998, Oncogene.

[42]  M. Loda,et al.  Low p27 expression predicts poor disease-free survival in patients with prostate cancer. , 1998, The Journal of urology.

[43]  D. Sidransky,et al.  Role of the p16 tumor suppressor gene in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Baljit Singh,et al.  Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus , 1998, Genes, chromosomes & cancer.

[45]  G. Riggins,et al.  Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. , 1998, Cancer research.

[46]  G. Finocchiaro,et al.  PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas , 1998, Oncogene.

[47]  W. Isaacs,et al.  Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. , 1998, Cancer research.

[48]  M. Raffeld,et al.  PTEN gene alterations in lymphoid neoplasms. , 1998, Blood.

[49]  M. Wolter,et al.  Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. , 1998, Cancer research.

[50]  G. Mills,et al.  MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. , 1997, Cancer research.

[51]  C. James,et al.  PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. , 1997, Cancer research.

[52]  K. Lunetta,et al.  Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome. , 1997, Cancer research.

[53]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.

[54]  C. Larsson,et al.  Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. , 1997, Cancer research.

[55]  A. Berchuck,et al.  PTEN/MMAC1 mutations in endometrial cancers. , 1997, Cancer research.

[56]  R. McLendon,et al.  PTEN gene mutations are seen in high-grade but not in low-grade gliomas. , 1997, Cancer research.

[57]  A. Sakurada,et al.  PTEN1 is frequently mutated in primary endometrial carcinomas , 1997, Nature Genetics.

[58]  J. Bruce,et al.  Somatic mutations of PTEN in glioblastoma multiforme. , 1997, Cancer research.

[59]  Kathleen R. Cho,et al.  Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. , 1997, Cancer research.

[60]  P. Guldberg,et al.  Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. , 1997, Cancer research.

[61]  M. Wigler,et al.  P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Esposito,et al.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. , 1997, Cancer research.

[63]  C. Eng,et al.  Germline mutations in PTEN are present in Bannayan-Zonana syndrome , 1997, Nature Genetics.

[64]  G. Thomas,et al.  Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers , 1997, International journal of cancer.

[65]  Jing Li,et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.

[66]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[67]  M. Loda,et al.  The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. , 1997, Cancer research.

[68]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[69]  V. Álvarez,et al.  Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. , 1997, Journal of clinical pathology.

[70]  P. Goodfellow,et al.  Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. , 1996, Cancer research.

[71]  L. Liotta,et al.  Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. , 1996, Cancer research.

[72]  J. Roth,et al.  Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. , 1996, The Journal of thoracic and cardiovascular surgery.

[73]  J. Sloan,et al.  Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. , 1995, Cancer research.

[74]  J. Abraham,et al.  The MTS1 gene is frequently mutated in primary human esophageal tumors. , 1994, Oncogene.

[75]  S. J. Darnton,et al.  Expression of p53 protein in oesophageal carcinoma: Clinicopathological correlation and prognostic significance , 1994, The British journal of surgery.

[76]  G. Thomas,et al.  TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. , 1994, Gastroenterology.

[77]  Carissa A. Sanchez,et al.  p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. , 1994, Gastroenterology.

[78]  F. Paraf,et al.  p53 protein expression in Barrett's adenocarcinoma: a frequent event with no prognostic significance , 1994, Histopathology.

[79]  Patricia L. Blount,et al.  Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. , 1992, Cancer research.

[80]  Max H. Myers,et al.  Manual for Staging of Cancer , 1992 .

[81]  Patricia L. Blount,et al.  Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[82]  J. Fraumeni,et al.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia. , 1991, JAMA.